Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

This publication has 38 references indexed in Scilit:

• 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
  Journal Of Hypertension, 2003
• Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  JAMA, 2002
• Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis
  Circulation, 2002
• A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
  New England Journal of Medicine, 2001
• Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial
  Blood Pressure, 2001
• Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension
  Journal Of Hypertension, 1998
• The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial of Cardiovascular Events in Hypertension. Rationale and Design
  Blood Pressure, 1998
• Electrocardiographic identification of left ventricular hypertrophy: Test performance in relation to definition of hypertrophy and presence of obesity
  Journal of the American College of Cardiology, 1996
• Valsartan: Preclinical and Clinical Profile of an Antihypertensive Angiotensin‐II Antagonist
  Cardiovascular Drug Reviews, 1995
• Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context
  Published by Elsevier ,1990